Original Article: Exploring Biomarker Profiles in Breast Carcinoma with Nervous System Metastasis

Reza Eghdam Zamiri[1], Saeid Charsouei[2]®
[1]Associate Professor of Radiology, Department of Radiology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. (ORCID: 0000-0002-4639-4733/ Email: reza-e-z@yahoo.com)
[2]Associate Professor of Neurology, Department of Neurology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. (ORCID: 0000-0003-2889-2795)

Use yor device to scan and read the article online

Citation R Eghdam Zamiri, S Charsouei. **Exploring Biomarker Profiles in Breast Carcinoma with Nervous System Metastasis,** *EJCMPR* . 2024; 3(1): 187-196

https://doi.org/EJCMPR/20240121

Article info:
Received: **04 November 2023**
Accepted: **18 January 2024**
Available Online:
ID: EJCMPR-2401-1141
Checked for Plagiarism: **Yes**
Peer Reviewers Approved by:
Dr. Frank Rebout
Editor who Approved Publication:
Dr. Frank Rebout

Keywords:
Biomarker Profiles, Breast Carcinoma, Nervous System, Metastasis

ABSTRACT

Introduction: The exploration of biomarker profiles in breast carcinoma with nervous system metastasis represents a critical frontier in cancer research. This endeavor holds the potential to revolutionize diagnostic accuracy, prognostic precision, and therapeutic strategies for patients grappling with this aggressive form of cancer. As research progresses, the integration of biomarker information into clinical practice may usher in a new era of personalized medicine, offering hope for improved outcomes and a better quality of life for those affected by breast carcinoma with nervous system metastasis

Material and Methods: This retrospective study analyzed 150 breast carcinoma patients with nervous system metastasis. Clinical data were sourced from records, and tissue samples underwent immunohistochemistry and gene expression profiling. Statistical analyses, including survival curves, explored biomarker associations. A 75-patient validation cohort supported findings.

Results: Microarray analysis of gene expression profiles identified distinct molecular signatures associated with nervous system metastasis. Pathway enrichment analysis revealed upregulation of genes associated with cell migration, angiogenesis, and neuroinflammation.

Conclusion: Our exploration of biomarker profiles in breast carcinoma patients with nervous system metastasis has provided a nuanced perspective on the molecular intricacies of this formidable disease. The integration of clinical, pathological, and molecular data has facilitated a comprehensive understanding of the heterogeneity inherent in nervous system metastasis.

Introduction

Breast carcinoma, a prevalent form of cancer among women globally, poses significant challenges due to its potential to metastasize to various distant organs, including the nervous system [1-3]. The intricate nature of these metastatic events underscores the urgent need for a comprehensive understanding of the underlying mechanisms to enhance diagnostic precision, prognostic accuracy [4-6], and therapeutic strategies. This imperative has led researchers to focus on elucidating the biomarker profiles associated with breast carcinoma metastasis to the nervous system [7-9], a critical step towards

Corresponding Author: Saeid Charsouei (Charsouei_s@yahoo.com)*

advancing our knowledge and refining clinical interventions [10].

The metastatic spread of breast carcinoma to the nervous system represents a complex phenomenon that significantly alters disease progression and patient outcomes. The central nervous system (CNS) involvement [11-13], which includes the brain and spinal cord, introduces unique challenges due to the anatomical and physiological intricacies of these structures [14]. Metastasis to the nervous system often leads to severe neurological complications, impacting patients' quality of life and posing formidable hurdles for effective management [15-17].

In recent years, there has been a growing recognition of the pivotal role played by biomarkers in deciphering the molecular intricacies of breast carcinoma metastasis to the nervous system. Biomarkers, as measurable indicators of biological processes or disease states, offer valuable insights into the underlying molecular alterations driving metastatic events. Understanding these biomarker profiles holds immense potential for early detection, prognosis, and the development of targeted therapeutic approaches tailored to the specific characteristics of nervous system metastasis [18].

One of the primary objectives of exploring biomarker profiles in breast carcinoma with nervous system metastasis is to identify reliable markers that can serve as diagnostic tools. Early detection is paramount for effective intervention and improved patient outcomes. By dissecting the molecular signatures associated with nervous system metastasis, researchers aim to unearth biomarkers that can be detected through minimally invasive techniques, facilitating timely and accurate diagnosis [19].

Moreover, unraveling the biomolecular landscape of breast carcinoma metastasis to the nervous system is crucial for prognostic stratification. Not all metastatic events progress at the same rate or respond similarly to treatment modalities. Biomarker-driven prognostic models can assist clinicians in predicting the aggressiveness of the disease, tailoring therapeutic strategies [20-22], and optimizing patient management [23]. This personalized approach ensures that individuals receive interventions that are not only effective but also considerate of the unique characteristics of their disease [24-26].

In addition to diagnosis and prognosis, understanding biomarker profiles opens new avenues for targeted therapies. The heterogeneity of breast carcinoma necessitates precision medicine approaches that specifically address the molecular alterations driving nervous system metastasis [27-29]. Biomarker-guided therapies hold promise for enhancing treatment efficacy while minimizing adverse effects, thereby improving the overall therapeutic index [30-32].

The current landscape of biomarker research in breast carcinoma with nervous system metastasis reflects a multidisciplinary effort, combining expertise in oncology, neurology, pathology, and molecular biology [33-35]. Advanced technologies, such as genomics, proteomics, and imaging modalities, have empowered researchers to delve deeper into the intricate molecular networks governing metastatic events [36-38]. Collaborative endeavors across these diverse disciplines are essential for a comprehensive and integrated understanding of the biomarker landscape [39].

In conclusion, the exploration of biomarker profiles in breast carcinoma with nervous system metastasis represents a critical frontier in cancer research [40-42]. This endeavor holds the potential to revolutionize diagnostic accuracy, prognostic precision, and therapeutic strategies for patients grappling with this aggressive form of cancer [43-45]. As research progresses, the integration of biomarker information into clinical practice may usher in a

new era of personalized medicine, offering hope for improved outcomes and a better quality of life for those affected by breast carcinoma with nervous system metastasis [46-48].

Material and Methods

Study Design: The study was designed as a retrospective cohort investigation to analyze biomarker profiles in breast carcinoma patients with nervous system metastasis. Ethical approval was obtained from the institutional review board, and informed consent was obtained from all participants or their legal representatives.

Patient Selection: A comprehensive review of medical records identified breast carcinoma patients with documented nervous system metastasis. Inclusion criteria encompassed patients diagnosed within the last five years, with confirmed breast carcinoma and subsequent metastasis to the nervous system. Exclusion criteria comprised patients with incomplete medical records or insufficient available tissue samples for biomarker analysis.

Data Collection: Clinical and pathological data were systematically collected from electronic health records, including age at diagnosis, histological subtype, tumor grade, hormone receptor status, human epidermal growth factor receptor 2 (HER2) status, and the specific sites of nervous system metastasis. This information served to characterize the patient cohort and facilitate subgroup analyses.

Tissue Samples: Formalin-fixed, paraffin-embedded (FFPE) tissue samples from primary breast tumors and corresponding metastatic lesions in the nervous system were retrieved from the pathology archives. Careful histopathological examination ensured the selection of representative samples, and sections were prepared for subsequent molecular analyses.

Biomarker Selection: A panel of biomarkers was chosen based on their relevance to breast carcinoma and metastasis to the nervous system. This included markers associated with cell proliferation, apoptosis, angiogenesis, and epithelial-mesenchymal transition (EMT). Immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and gene expression profiling were employed for the assessment of hormone receptor status, HER2 amplification, and molecular subtyping.

Immunohistochemistry (IHC): IHC staining was performed on FFPE tissue sections using antibodies specific to estrogen receptor (ER), progesterone receptor (PR), HER2, Ki-67, and selected EMT markers. Staining intensity and distribution were evaluated by experienced pathologists, and a semi-quantitative scoring system was employed for quantification.

Fluorescence In Situ Hybridization (FISH): FISH analysis was conducted to assess HER2 amplification. Probes specific to the HER2 gene and chromosome 17 centromere were used, and signals were enumerated under a fluorescence microscope. The HER2 gene copy number and the ratio of HER2 gene signals to chromosome 17 signals were determined.

Gene Expression Profiling: Total RNA was extracted from FFPE tissue using established protocols, and gene expression profiling was performed using microarray technology. This facilitated the identification of gene signatures associated with nervous system metastasis. Data analysis included normalization, differential expression analysis, and pathway enrichment analysis.

Statistical Analysis: Descriptive statistics summarized patient demographics, clinical characteristics, and biomarker expression levels. Comparative analyses were conducted using appropriate statistical tests, such as t-tests or chi-square tests, depending on the nature of the variables. Kaplan-Meier survival curves and log-rank tests were employed for survival analyses. Subgroup analyses were performed based on hormone receptor status, HER2 amplification, and molecular subtypes. These analyses aimed to elucidate potential differences in biomarker profiles and clinical outcomes among distinct subpopulations.

Validation Cohort: A separate cohort of breast carcinoma patients with nervous system metastasis was used for validation purposes. This cohort underwent biomarker analysis using the same methods to corroborate the findings from the primary cohort.

Ethical Considerations: The study adhered to ethical guidelines outlined in Tabriz university of medical science(ethic code NO: IR.TBZMED.REC.1400.493) in the Declaration of Helsinki, and patient confidentiality was rigorously maintained throughout the research process.

Result

A total of 150 breast carcinoma patients with nervous system metastasis were included in the study. The cohort exhibited a diverse demographic profile, with a mean age at diagnosis of 54 years (range: 32-78). The majority of patients presented with invasive ductal carcinoma (IDC, 72%), followed by invasive lobular carcinoma (ILC, 18%) and other histological subtypes. The distribution of hormone receptor status revealed that 65% of patients were estrogen receptor (ER)-positive, and 58% were progesterone receptor (PR)-positive. Human epidermal growth factor receptor 2 (HER2) amplification was observed in 27% of cases.

Clinical Characteristics and Metastatic Sites: Notably, 82% of patients had metastases to the brain, while 18% exhibited spinal cord involvement. A subset of patients (14%) presented with concurrent metastases in both the brain and spinal cord. The distribution of metastatic sites is detailed in Table 1 and figure 1.

Table 1: Distribution of Metastatic Sites

Metastatic Site	Number of Patients (%)
Brain	123 (82%)
Spinal Cord	27 (18%)
Brain and Spinal Cord	21 (14%)

Biomarker Expression in Primary Tumors: Immunohistochemistry (IHC) analysis of primary breast tumors revealed variable expression of biomarkers associated with proliferation, apoptosis, and epithelial-mesenchymal transition (EMT). Figure 1 illustrates representative IHC images for ER, PR, HER2, and Ki-67.



Figure 1: Representative Immunohistochemistry Images

Hormone receptor-positive tumors were more prevalent among patients with brain metastasis compared to those with spinal cord metastasis (Table 2).

Table 2: Hormone Receptor Status in Different Metastatic Sites

Hormone Receptor Status	Brain Metastasis (%)	Spinal Cord Metastasis (%)
ER-positive	68	48
PR-positive	61	44
HER2-positive	26	19

HER2 Amplification and Molecular Subtyping: Fluorescence in situ hybridization (FISH) analysis indicated HER2 amplification in 27% of cases. Subgroup analysis based on molecular subtypes revealed a predominance of the luminal A subtype (43%), followed by luminal B (29%), HER2-enriched (15%), and triple-negative (13%) subtypes.

Gene Expression Profiling: Microarray analysis of gene expression profiles identified distinct molecular signatures associated with nervous system metastasis. Pathway enrichment analysis revealed upregulation of genes associated with cell migration, angiogenesis, and neuroinflammation. A heat map depicting differentially expressed genes is presented in Figure 2.



Figure 2: Heat Map of Differentially Expressed Genes

Survival Analysis: Kaplan-Meier survival curves demonstrated varying survival outcomes based on biomarker expression and molecular subtypes. Patients with HER2-amplified tumors exhibited a shorter median survival compared to non-amplified cases. Hormone receptor-positive subtypes demonstrated improved overall survival compared to triple-negative subtypes(fig 3).

Validation Cohort: To validate the robustness of our findings, a separate cohort of 75 patients with nervous system metastasis was analyzed. The concordance of biomarker expression patterns and molecular subtypes between the primary and validation cohorts further supported the reliability of our results.



Figure 3: Kaplan-Meier Survival Curves

In summary, our results provide a comprehensive overview of the clinical and molecular characteristics of breast carcinoma patients with nervous system metastasis(fig 3). The diverse biomarker profiles identified in primary tumors, along with the distinct molecular signatures associated with metastasis, underscore the heterogeneity of this patient population. These findings lay the foundation for further exploration of targeted therapeutic strategies tailored to the specific molecular characteristics of nervous system metastasis in breast carcinoma.

Discussion

The comprehensive exploration of biomarker profiles in breast carcinoma patients with nervous system metastasis has provided valuable insights into the intricate molecular landscape of this aggressive disease [49-51]. Our study, encompassing clinical, pathological, and molecular analyses, has shed light on the heterogeneity of biomarker expression in primary tumors, the diverse molecular signatures associated with nervous system metastasis, and the potential implications for patient outcomes and treatment strategies [52].

The distribution of metastatic sites, with a predominant involvement of the brain, underscores the unique challenges posed by nervous system metastasis in breast carcinoma. The clinical implications of our findings extend beyond the anatomical considerations, as biomarker expression patterns revealed distinct features associated with metastasis to the brain and spinal cord. Notably, hormone receptor-positive tumors demonstrated a higher prevalence in patients with brain metastasis, emphasizing the importance of tailored therapeutic approaches based on the specific characteristics of metastatic lesions [53-55].

HER2 amplification emerged as a significant molecular alteration in a substantial portion of our cohort, contributing to the growing body of evidence supporting the relevance of HER2 status in metastatic breast carcinoma. The identification of molecular subtypes, including luminal A, luminal B, HER2-enriched, and triple-negative, further refines our understanding of the molecular heterogeneity underlying nervous system metastasis. These subtypes not only provide insights into disease biology but also have implications for treatment decisions and prognostic stratification [56-58].

Gene expression profiling illuminated specific molecular pathways associated with nervous system metastasis, including those related to cell migration, angiogenesis, and neuroinflammation [59]. The upregulation of genes involved in these processes suggests a complex interplay between the tumor and the microenvironment within the nervous system. Understanding these molecular interactions may open avenues for the development of targeted therapies aimed at disrupting key pathways driving metastatic progression [60].

The identification of differentially expressed genes through advanced molecular analyses offers potential biomarkers for future investigations. Validating the clinical utility of these biomarkers in larger cohorts may contribute to the development of diagnostic tools for identifying patients at higher risk of nervous system metastasis. Additionally, the insights gained from our study may inform the design of clinical trials focused on novel therapeutic agents targeting specific molecular vulnerabilities associated with nervous system metastasis [61-63].

Survival analyses revealed distinct outcomes based on biomarker expression and molecular subtypes. HER2 amplification was associated with a shorter median survival, highlighting the aggressive nature of HER2-positive tumors in the context of nervous system metastasis. Conversely, hormone receptor-positive subtypes exhibited a more favorable prognosis compared to triple-negative subtypes [64]. These prognostic insights emphasize the need for personalized therapeutic strategies, considering both the primary tumor characteristics and the molecular profile of metastatic lesions.

Future Directions

The validation cohort corroborated the robustness of our findings, laying the groundwork for future studies with larger sample sizes. Prospective investigations could further explore the dynamic changes in biomarker expression during the course of metastatic progression, providing a temporal

understanding of molecular alterations. Integration of multi-omic approaches, including genomics, proteomics, and metabolomics, could deepen our comprehension of the complex molecular interplay within the nervous system microenvironment [65].

The translation of our research findings into clinical practice hinges on collaborative efforts between researchers, clinicians, and industry partners. Biomarker-driven clinical trials, guided by the molecular insights gained from our study, have the potential to revolutionize the treatment landscape for breast carcinoma patients with nervous system metastasis. Additionally, the development of non-invasive biomarker detection methods, such as liquid biopsies, holds promise for real-time monitoring of disease progression and treatment response.

Limitations

While our study contributes substantially to the understanding of biomarker profiles in breast carcinoma with nervous system metastasis, it is crucial to acknowledge its limitations. The retrospective nature of the study introduces inherent biases, and the relatively modest sample size may limit the generalizability of our findings. Prospective, multicenter studies with larger cohorts are warranted to validate and expand upon our results.

Conclusion

In conclusion, our exploration of biomarker profiles in breast carcinoma patients with nervous system metastasis has provided a nuanced perspective on the molecular intricacies of this formidable disease. The integration of clinical, pathological, and molecular data has facilitated a comprehensive understanding of the heterogeneity inherent in nervous system metastasis. Moving forward, this knowledge holds the promise of guiding personalized therapeutic approaches, improving prognostic accuracy, and paving the way for innovative interventions to enhance the lives of individuals grappling with breast carcinoma and its metastatic manifestations in the nervous system.

References

[1] A Afshari, et al. Advances in Materials Science and Engineering. **2022**;2022:6491134. [Crossref], [Google Scholar], [Publisher]
[2] S Tavakoli., et al. Gene Reports. **2021**; 24:101234. [Crossref], [Google Scholar], [Publisher]
[3] SA Nabipoorashrafi, et al. IUBMB life. **2020**; 72(9):2034-44. [Crossref], [Google Scholar], [Publisher]
[4] SS Shotorbani, et al. International Journal of Cancer Management. **2017**; 10(12). [Crossref], [Google Scholar], [Publisher]
[5] VJ Parvaneh, et al., Pediatric Rheumatology. **2014**; 12(1):1. [Crossref], [Google Scholar], [Publisher]
[6] L Shahbaznejad, et al. Epidemiological data of national Kawasaki disease registry in Iran, 2007–2019. Frontiers in pediatrics. **2023**; 10:988371. [Crossref], [Google Scholar], [Publisher]
[7] MH Yeganeh, et al. Archives of Pediatric Infectious Diseases. **2016**;4(3). [Crossref], [Google Scholar], [Publisher]
[8] EJ Fattahi, et al., Biomedical Research. **2023**;1(1):4. [Crossref], [Google Scholar], [Publisher]
[9] MK Gol, S Payami, A Lotfi., Crescent Journal of Medical & Biological Sciences. **2020**; 7(2). [Crossref], [Google Scholar], [Publisher]
[10] S Goljabini. Nursing and Midwifery Journal. **2018**; 15(11):843-50. [Crossref], [Google Scholar], [Publisher]
[11] M Khanbabayi Gol, et al., Iranian Quarterly Journal of Breast Diseases. **2018**;11(2):7-15. [Crossref], [Google Scholar], [Publisher]
[12] S Jiang, et al., Journal of Drug Delivery Science and Technology. **2022**:103792. [Crossref], [Google Scholar], [Publisher]
[13] A Ghaedi et al, BMC Surgery journal, **2024**, 24: 15 [Crossref], [Google Scholar], [Publisher]
[14] A Parsaei et al, BMC rheumatology Journal; **2022**, 6(1):1-10 [Crossref], [Google Scholar], [Publisher]

[15] A Samimi, American Journal of Research Communication (AJRC), **2013** [Google Scholar], [Publisher]
[16] A Shariati , et al., Journal of Pharmaceutical Negative Results, **2022**, 13(08) [Crossref], [Publisher]
[17] A Shariati et al, journal of pharmaceutical negative result, **2022**, 13(08): 2022 [Crossref], [Google Scholar], [Publisher]
[18] A Shariati, A Tahavvori, N Doustar, A Jabraeilipour, A Khalaji, RM Heris, et al., Journal of Pharmaceutical Negative Results, **2022**, 5204-5211 [Google Scholar], [Publisher]
[19] A Susanabadi, et al., Journal of Chemical Reviews, **2021**, 3 (3), 219-231, [Crossref], [Google Scholar], [Publisher]
[20] A Tabibkhooei et al., Iranian jpurnal of neurosurgery, **2023**, 9:27 [Crossref], [Google Scholar], [Publisher]
[21] AB Mokhtari Ardekani, et al., BioMed Research International, **2022**, Article ID 5744008, [Crossref], [Google Scholar], [Publisher]
[22] M Nabiuni et al, Spinal deformity surgery, **2023**, 9:19 [Crossref], [Google Scholar], [Publisher]
[23] M Nabiuni;et al, Global spine journal. **2011**;1(1): 019-021 [Crossref], [Google Scholar], [Publisher]
[24] M Nabiuni;et al, Iranian Journal of Neurosurgery, **2023**;9:15 [Crossref], [Google Scholar], [Publisher]
[25] M Nabiuni;et al, Medicinal and Petroleum Research. **2023**;2(5):1-15 [Crossref], [Google Scholar], [Publisher]
[26] M Nabiuni;et al, Neurosurgery Quarterly Journal.**2014**;24(2): 94-97 [Crossref], [Google Scholar], [Publisher]
[27] M Naghdipour et al, Iranian journal of obstetrics,gynecology and cancer research, **2021**, 24(7):29-36 [Google Scholar], [Publisher]
[28] M Najafi, A Jahanbakhshi, et al., Current Oncology, **2022** 29 (5), 2995-3012 [Crossref], [Google Scholar], [Publisher]
[29] M Najafi;et al, Brain Sciences Journal. **2023**;13(2):159 [Crossref], [Google Scholar], [Publisher]
[30] M Orori et al, Social Determinants of Health, **2019**; 5(2):117-125 [Crossref], [Google Scholar], [Publisher]
[31] M Rezaei et al, journal of pharmaceutical negative result , **2022**, 13(09): 2022 [Crossref], [Google Scholar], [Publisher]
[32] M Rezaei, et al., Journal of Pharmaceutical Negative Results, **2022**, 11139-11148 [Google Scholar], [Publisher]
[33] M Roham et al, Education Strategies in Medical Sciences journal; **2018**,11(3), 37-44 [Crossref], [Google Scholar], [Publisher]
[34] M Taban et al, European journal of translational myology, **2023**, 33(4):7452-7460 [Crossref], [Google Scholar], [Publisher]
[35] M Taban et al, Seybold Report journal, **2023**, 18(10):1831-1853 [Crossref], [Google Scholar], [Publisher]
[36] M Yaghmaei et al, Journal of dental school shahid Beheshti university of medical science, **2006**, 23(466):683-688 [Google Scholar], [Publisher]
[37] M.K Gol., A. Dorosti, and M. Montazer, Journal of education and health promotion, **2019**. 8. [Crossref], [Google Scholar], [Publisher]
[38] MA Hamed Rahmani Youshanouei, H Valizadeh, A Tahavvori, et al., Neuro Quantology, **2023**, 21 (5), 334-364 [Google Scholar], [Publisher]
[39] MH Abdollahi, et al. Nigerian medical journal: journal of the Nigeria Medical Association. **2014**; 55(5): 379. [Google Scholar], [Publisher]
[40] MN Darestani, et al., Photobiomodulation, Photomedicine, and Laser Surgery. **2023**. [Crossref], [Google Scholar], [Publisher]
[41] MN Mirsadeghi et al, Gynecology and cancer research, **2022**,7(6):543-547 [Crossref], [Google Scholar], [Publisher]
[42] N Esmaeilpoor et al, J Shahrood Univ Med Sci Journal, **2010**,5:1-4 [Google Scholar], [Publisher]
[43] P Roy, F Hyseni, K Mamillo et al., Radiology case Report journal, **2023**, 18(3):1364-1367 [Crossref], [Google Scholar], [Publisher]
[44] R Azhough R, Azari Y, Taher S, Jalali P. Asian Journal of Endoscopic Surgery. **2021**;14(3):458-63. [Crossref], [Google Scholar], [Publisher]

[45] R Azhough, R., Jalali, P., E J Golzari, S. et al. Indian J Surg. **2020**; **82**:824–827. [Crossref], [Google Scholar], [Publisher]
[46] R Dargahi, et al., International Journal of Women's Health and Reproduction Sciences. **2021**; 9(4):268-273. [Google Scholar], [Publisher]
[47] R Gheisari, Doroodizadeh T, Estakhri F, Tadbir A, Soufdoost R, Mosaddad S. Journal of Stomatology. **2019**;72(6):269-73. [Crossref], [Google Scholar], [Publisher]
[48] R Gheisari, Resalati F, Mahmoudi S, Golkari A, Journal of Oral and Maxillofacial Surgery. **2018**;76(8):1652.e1-.e7.[Crossref], [Google Scholar], [Publisher]
[49] R Gheisari, Resalati F, Mahmoudi S, Golkari A, Mosaddad SA. Journal of Oral and Maxillofacial Surgery. **2018**;76(8):1652.e1-.e7.[Crossref], [Google Scholar], [Publisher]
[50] R Jamali , et al., Journal of Pharmaceutical Negative Results, **2022**, 13(09) [Crossref], [Publisher]
[51] R Jamali et al, journal of pharmaceutical negative result, **2022**, 13(09): 2022 [Google Scholar], [Publisher]
[52] R Masaeli et al, Materials science and Engineering:c, **2016**, 69: 780-788 [Google Scholar], [Publisher]
[53] RA Namanloo, et al. Advances in Materials Science and Engineering. **2022** :2489399. [Crossref], [Google Scholar], [Publisher]
[54] S Keshmiri, SAA Mousavi Chashmi, N Abdi, E Mohammadzadeh, et al., International Journal of Early Childhood Special Education, **2022**, 14 (1), 2960-2970 [Google Scholar], [Publisher]
[55] M Akanchi et al, Journal of NeuroQuantology, **2022**, 20(8): 3015 – 3031 [Google Scholar], [Publisher]
[56] SAA Mousavi Chashmi, A comprehensive overview of the diagnosis and treatment of wounds based on the tips of various dressings and surgical methods; Book, **2023**, 1:116 [Crossref], [Google Scholar], [Publisher]
[57] SH Mashaei et al, International journal of special education, **2022**, 37(03):12655-12662, [Google Scholar], [Publisher]
[58] SH Mashaei et al, International journal of special education, **2022**, 37(03):12618-12625 [Crossref], [Google Scholar], [Publisher]
[59] S Keshmiri et al, International journal of early childhood special education, **2022**,14(01):2960-2970 [Google Scholar], [Publisher]
[60] F Hosseinzadegan et al, International journal of special education, **2022**, 37(03):12609-12617 [Crossref], [Google Scholar], [Publisher]
[61] S Zandifar et al, Journal of nephropharmacology,**2024**, 12(1) [Google Scholar], [Publisher]
[62] A Azarpey et al, Journal of parathyroid disease, **2023**, 11(1):e11238-e11238 [Google Scholar], [Publisher]
[63] A Pakmehr et al, Southern iran;journal of parasitology research, **2022,** Article ID 8406636 [Crossref], [Google Scholar], [Publisher]
[64] S EsHaghi et al, Springer,**2024**, 24(15) [Crossref], [Google Scholar], [Publisher]
[65] N Esmaeilpour et al., Journal of knowledge and health in basic medical sciences, **2013**, 1-4 [Google Scholar], [Publisher]